InvestorsHub Logo
Followers 1083
Posts 26884
Boards Moderated 11
Alias Born 01/11/2016

Re: None

Wednesday, 11/29/2023 7:23:38 PM

Wednesday, November 29, 2023 7:23:38 PM

Post# of 7149
No publicity, just filings. I wonder how they are willing to keep this under wrap, they offices. The President owns the whole OS and control 99% of this ticker and his primary address is in Dubai. Offices Headquarters: City of Neuss in Germany: 440 sqm (monthly rent 5.000 €) City of Bruckmühl in Germany: 90 sqm (monthly rent 1.500 €). Current market cap is 110 million, price tag for the acquisition they just made 500 million dollars for Hydrogel Tech, just barely under $4.50, this President can't unload his shares here in the OTC, won't make sense, with this 500,000 float, with reasonable volume this can hit 8-10 dollars at some point, I will give it about 4-6 weeks for things to unfold, once the street discover this and looks like based on the filings they could be aiming going Nasdaq. You simply can't go wrong with a small float like this one, impeccable tech, a company that has sales and been around for 10 years, slick website that makes you go awe. Just needs more eyes on it and in-fact with the right volume this could potentially hit 20 dollars, talking about million plus volume and if this was Nasdaq it would have done that in heartbeat.
Dubai, United Arab Emirates: 50 sqm (monthly rent 1.500 €)

"The CS Protect- Hydrogel is a hydrogel-based tissue spacer. It is used in radiation therapy to increase the distance between cancer cells and healthy tissue and thus protect healthy tissue from damage caused by high doses of radiation. Currently, hydrogel spacers are used exclusively in the treatment of prostate cancer. Here, the spacer pushes the rectum away from the prostate, thus reducing rectal damage from radiation therapy. The hydrogel spacer is injected once in liquid form through a thin needle into the space between cancer cells and healthy tissue and is broken down by the body after about six months. The CS Protect-Hydrogel is a "ready-to-use" product, which is sterile packed and can be applied directly. The hydrogel can be used in radiotherapy for prostate, cervical, esophageal, bladder and breast cancer."

"On September 27, 2023, CS Diagnostics Corp, acquired 100% of the CS Protect-Hydrogel for a cost basis of Five Hundred Million USD in the form of 110,000,000 shares of CS Diagnostics Corp Common Stock. On November, 2023, CS Diagnostics Corp. filed its 3rd Quarter Report and Financial Statements with the consent of our PCAOB Auditors which represent the purchase of the CS Protect-Hydrogel. The issuer is requesting OTC Markets recognize the Issuer is no longer a shell and certainly not to be construed as a “Shell Risk”.
The issuer is now working with its partners to apply for approval of CS Protect Hydrogel with the relevant national regulatory authorities in Europe, North and South America."

“The value of the CS Diagnostics Group's right to use CS Protect-Hydrogel is mainly dependent on the market penetration and the market share achieved as well as the achievable sales prices. In the most likely scenario of a market share of 50 % and sales prices of EUR/unit 1,100 (EUR (27)) and EUR/unit 1,900 (USA), the economic benefit as the net present value of future cash surpluses as of September 30, 2023, is EUR 961 million.”